Skip to main content
. 2024 Feb 16;15:1339167. doi: 10.3389/fneur.2024.1339167

Table 2.

Incidence rate and prevalence estimates of MG in the USA from commercial and Medicare claims data (2017).

2017 US population (ACS) Incidence
(cases per 1,000,000 person-years)
Prevalence
(cases per 1,000,000 persons)
Females Males Females Males Overall Standardizeda Females Males Overall Standardizeda
All 129,341,135 122,729,360 53.89 55.30 54.55 68.48 202.19 191.37 197.07 316.35
Age group, years
18–34 37,214,265 38,571,882 21.79 5.24 13.69 13.37 75.03 22.35 49.48 48.22
35–44 20,646,170 20,471,735 36.66 22.83 30.22 29.78 143.66 67.97 108.06 105.98
45–54 21,440,066 20,890,889 39.86 42.92 41.30 41.38 197.26 116.93 159.46 157.62
55–64 21,745,371 20,274,405 74.00 95.29 83.94 84.28 280.14 335.07 305.81 306.65
≥65 28,295,263 22,520,449 166.54 222.83 191.89 191.49 782.27 1,333.88 1,030.27 1,026.74

aStandardized to the 2017 ACS US population.

ACS, American Community Survey; MG, myasthenia gravis.